NEU 6.41% $15.27 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1298

  1. 956 Posts.
    lightbulb Created with Sketch. 331
    Will be interesting to see what comes out of this conference.

    Obviously the P3 PMS meeting with the FDA is very important but I do think these meetings/conferences following 3 successful P2 trials will be very instructive in terms of gauging interest in the company and our pipeline.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.